中文 | English
Return
Total: 1238 , 1/124
Show Home Prev Next End page: GO
MeSH:(5 Fluorouracil)

1.Assessment of the trabeculectomy with 5 fluoruoracil in the treatment of post-traumatic glaucoma

Yen Thi Thu Nguyen

Journal of Medical Research 2008;59(6):59-64

2.The Effect of Minoxidil on Cultured Mouse Fibroblast.

Jae Hyong BAE ; Kuhl HUH

Journal of the Korean Ophthalmological Society 1996;37(10):1670-1677

3.Synergistic Effect of Parthenolide in Combination with 5-Fluorouracil in SW480 Cells.

Se Lim KIM ; Thu Trang Thi KIEU ; Byung Jun JEON ; Seong Hun KIM ; In Hee KIM ; Seung Ok LEE ; Soo Teik LEE ; Sang Wook KIM

Intestinal Research 2012;10(4):357-364

4.Clinical Pharmacokinetics of Tegafur Administered with Epirubicin and Cisplatin in Patients with Advanced Gastric Cancer.

Jin Hyung KANG ; Yoo Lim KIM ; Hea Kyoung CHO ; Eun Sook LEE ; Soo Jin CHA ; Young Sun HONG ; Kyung Shik LEE ; Hyo Jeong KUH

Cancer Research and Treatment 2003;35(3):224-231

5.A Case of Fixed Drug Eruption Induced by Tegafur-Uracil(TEGASIL).

Young Soo HEO ; Hae Jun SONG ; Chil Hwan OH

Korean Journal of Dermatology 2010;48(2):155-157

6.Clearance of Actinic Keratosis Caused by the Prodrug of 5-Fluorouracil.

In Ho PARK ; Sang Min HWANG ; Sung Ku AN

Korean Journal of Dermatology 1999;37(10):1528-1531

7.Acral Erythema and Hyperpigmentation Induced by Tegafur.

Seog Jun HA ; Sang Hee HAM ; Young Min PARK ; Sang Hyun CHO ; Baik Kee CHO

Korean Journal of Dermatology 1998;36(2):363-366

8.Discoid Lupus Erythematosus-like Eruption Induced by Tegafur - Uracil (UFT).

Junghee YOON ; Soo Hong SEO ; Young Chul KYE ; Hyo Hyun AHN

Korean Journal of Dermatology 2010;48(11):1004-1007

10.XELOX ± Bevacizumab compared to FOLFOX4 ± Bevacizumab in first line metastatic colorectal cancer in a non-reimbursed health care system: A cost analysis.

Tan Jerry Y. ; Yacat Andrew A ; Sacdalan Dennis L.

Acta Medica Philippina 2015;49(2):64-67

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 1238 , 1/124 Show Home Prev Next End page: GO